Therapeutic uses of inhibitors of RTP801

Details for Australian Patent Application No. 2005277508 (hide)

Owner Quark Pharmaceuticals, Inc Silence Therapeutics AG

Inventors Kaufmann, Jorg; Feinstein, Elena; Giese, Klaus

Agent Allens Arthur Robinson

Pub. Number AU-B-2005277508

PCT Pub. Number WO2006/023544

Priority 04019405.2 16.08.04 EP; 60/688,943 08.06.05 US; 60/601,983 17.08.04 US; 60/609,786 14.09.04 US; 60/604,668 25.08.04 US; 60/638,659 22.12.04 US; 60/664,236 22.03.05 US

Filing date 16 August 2005

Wipo publication date 2 March 2006

Acceptance publication date 14 April 2011

International Classifications

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

1 March 2007 PCT application entered the National Phase

  PCT publication WO2006/023544 Priority application(s): WO2006/023544

5 March 2009 Alteration of Name

  The name of the applicant has been altered to Quark Pharmaceuticals, Inc; Silence Therapeutics AG 2006

14 April 2011 Application Accepted

  Published as AU-B-2005277508

11 August 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005277510-Process for plasmid DNA fermentation

2005277507-Landmark case identification system and method